[Corrigendum] Celecoxib inhibits the epithelial‑to‑mesenchymal transition in bladder cancer via the miRNA‑145/TGFBR2/Smad3 axis

Int J Mol Med. 2023 Aug;52(2):64. doi: 10.3892/ijmm.2023.5267. Epub 2023 Jun 16.

Abstract

Following the publication of the above article, an interested reader drew to the authors' attention that, for the Transwell migration assays shown in Figs. 1B and 3B on p. 685 and p. 688 respectively, the images selected for the '5637 / DMSO' experiment in Fig. 1B and the DMSO experiment in Fig. 3B were apparently the same, such that these data appeared to have been derived from the same original source. After having consulted their original data, the authors have realized that the 5637 DMSO data panel in Fig. 3B had been selected incorrectly. The revised version of Fig. 3, showing the correct data for the DMSO experiment in Fig. 3B, is shown on the next page. The authors regret that these errors went unnoticed prior to the publication of this article, and thank the Editor of International Journal of Molecular Medicine for allowing them the opportunity to publish this corrigendum. All the authors agree with the publication of this corrigendum; furthermore, they also apologize to the readership of the journal for any inconvenience caused. [International Journal of Molecular Medicine 44: 683‑683, 2019; DOI: 10.3892/ijmm.2019.4241].

Keywords: bladder cancer; celecoxib; microRNA‑145.

Publication types

  • Published Erratum